Verastem, Inc.
VSTM
Rank in Stocks
#8437
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the... Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Share Price
$8.70
Last synced: 2026-11-09
Market Cap
$1.06B
Change (1 day)
3.45%
Change (1 year)
2.96%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Verastem, Inc. (VSTM)
Category
Healthcare
Operating Margin for Verastem, Inc. (VSTM)
Operating Margin as of November 2026 TTM: -182.57%
According to Verastem, Inc.'s latest financial reports, its current operating margin (TTM) is -182.57%. At the end of 2025 the company had an operating margin of -550.33%.
Operating Margin history for Verastem, Inc. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -182.57% | -66.83% |
| 2025 | -550.33% | -52.13% |
| 2024 | -1,149.56% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -2,809.59% | -6.07% |
| 2021 | -2,991.18% | 5,264.38% |
| 2020 | -55.76% | -92.65% |
| 2019 | -758.14% | 113.71% |
| 2018 | -354.75% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.21% |
US
|
|
| -149.01% | -99.18% |
US
|
|
| 25.57% | -100.14% |
AU
|
|
| 31.23% | -100.17% |
BE
|
|
| 29.35% | -100.16% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Verastem, Inc.'s operating margin
What is Verastem, Inc.'s operating margin?
Verastem, Inc.'s operating margin is -182.57%, as of Nov 2026.
What was Verastem, Inc.'s operating margin in 2025?
In 2025, Verastem, Inc.'s operating margin was -550.33%, compared with -1,149.56% in 2024.
How has Verastem, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Verastem, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2021 (-2,991.18%).
How does Verastem, Inc.'s operating margin compare with similar companies?
Verastem, Inc.'s operating margin (-182.57%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.